Halozyme Therapeutics, Inc. (0J2O.L)
USD 48.78
(0.12%)
USD 48.78
(0.12%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 451.94 Million USD | 35.97% |
| 2022 | 315.5 Million USD | 12.6% |
| 2021 | 259.04 Million USD | 91.26% |
| 2020 | 152.96 Million USD | 313.36% |
| 2019 | -56.55 Million USD | 2.48% |
| 2018 | -69.33 Million USD | -185.59% |
| 2017 | 83.16 Million USD | 197.35% |
| 2016 | -79.47 Million USD | -203.11% |
| 2015 | -25.35 Million USD | 56.45% |
| 2014 | -61.03 Million USD | 21.63% |
| 2013 | -78.97 Million USD | -49.99% |
| 2012 | -52.47 Million USD | -170.23% |
| 2011 | -18.67 Million USD | 63.06% |
| 2010 | -52.74 Million USD | 5.78% |
| 2009 | -56.91 Million USD | -15.44% |
| 2008 | -49.38 Million USD | -79.11% |
| 2007 | -28.15 Million USD | -79.76% |
| 2006 | -14.5 Million USD | -12.45% |
| 2005 | -13.35 Million USD | -52.23% |
| 2004 | -8.96 Million USD | -11229.95% |
| 2003 | -79.09 Thousand USD | -452.66% |
| 2002 | -14.31 Thousand USD | 64.01% |
| 2001 | -39.76 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 137.59 Million USD | 18.88% |
| 2024 Q1 | 115.74 Million USD | -8.92% |
| 2024 Q3 | 163.19 Million USD | 38.11% |
| 2023 FY | - USD | 35.97% |
| 2023 Q1 | 71.63 Million USD | -9.39% |
| 2023 Q2 | 115.08 Million USD | 60.65% |
| 2023 Q4 | 121.72 Million USD | 12.07% |
| 2023 Q3 | 108.62 Million USD | -5.62% |
| 2022 Q4 | 79.06 Million USD | -29.72% |
| 2022 Q3 | 112.49 Million USD | 141.37% |
| 2022 Q1 | 76.44 Million USD | 35.22% |
| 2022 Q2 | 46.6 Million USD | -39.04% |
| 2022 FY | - USD | 12.6% |
| 2021 Q4 | 56.53 Million USD | -25.94% |
| 2021 Q3 | 76.33 Million USD | -18.6% |
| 2021 Q1 | 51.47 Million USD | -33.69% |
| 2021 Q2 | 93.78 Million USD | 82.2% |
| 2021 FY | - USD | 91.26% |
| 2020 Q3 | 41.1 Million USD | 35.3% |
| 2020 FY | - USD | 313.36% |
| 2020 Q4 | 77.62 Million USD | 88.86% |
| 2020 Q2 | 30.37 Million USD | 1383.98% |
| 2020 Q1 | -2.36 Million USD | 92.62% |
| 2019 Q1 | 3.95 Million USD | 5671.83% |
| 2019 FY | - USD | 2.48% |
| 2019 Q4 | -32.06 Million USD | -36.23% |
| 2019 Q3 | -23.53 Million USD | -81.84% |
| 2019 Q2 | -12.94 Million USD | -427.17% |
| 2018 Q4 | -71 Thousand USD | 99.71% |
| 2018 FY | - USD | -185.59% |
| 2018 Q1 | -23.14 Million USD | -118.38% |
| 2018 Q2 | -19.45 Million USD | 15.96% |
| 2018 Q3 | -24.86 Million USD | -27.81% |
| 2017 Q3 | 8.57 Million USD | 134.42% |
| 2017 Q4 | 125.92 Million USD | 1368.9% |
| 2017 Q1 | -26.92 Million USD | -19.26% |
| 2017 Q2 | -24.9 Million USD | 7.49% |
| 2017 FY | - USD | 197.35% |
| 2016 Q3 | -22.08 Million USD | -4.69% |
| 2016 Q2 | -21.1 Million USD | -34.57% |
| 2016 Q1 | -15.68 Million USD | -386.92% |
| 2016 FY | - USD | -203.11% |
| 2016 Q4 | -22.57 Million USD | -2.2% |
| 2015 Q3 | -22.83 Million USD | -593.62% |
| 2015 Q1 | -13.49 Million USD | -250.3% |
| 2015 Q4 | 5.46 Million USD | 123.93% |
| 2015 FY | - USD | 56.45% |
| 2015 Q2 | 4.62 Million USD | 134.29% |
| 2014 Q3 | -18.56 Million USD | -28.04% |
| 2014 FY | - USD | 21.63% |
| 2014 Q4 | -3.85 Million USD | 79.25% |
| 2014 Q2 | -14.49 Million USD | 41.6% |
| 2014 Q1 | -24.82 Million USD | -16.41% |
| 2013 Q4 | -21.32 Million USD | -17.21% |
| 2013 Q1 | -18.2 Million USD | -312.99% |
| 2013 FY | - USD | -49.99% |
| 2013 Q2 | -21.82 Million USD | -19.9% |
| 2013 Q3 | -18.19 Million USD | 16.64% |
| 2012 Q3 | -20.02 Million USD | -42.58% |
| 2012 Q1 | -14.9 Million USD | 18.05% |
| 2012 Q2 | -14.04 Million USD | 5.73% |
| 2012 Q4 | -4.4 Million USD | 78.0% |
| 2012 FY | - USD | -170.23% |
| 2011 Q1 | -9.33 Million USD | 46.79% |
| 2011 FY | - USD | 63.06% |
| 2011 Q4 | -18.18 Million USD | -452.89% |
| 2011 Q3 | 5.15 Million USD | 52.33% |
| 2011 Q2 | 3.38 Million USD | 136.24% |
| 2010 Q3 | -12.06 Million USD | -2.6% |
| 2010 Q4 | -17.54 Million USD | -45.33% |
| 2010 FY | - USD | 5.78% |
| 2010 Q1 | -11.37 Million USD | 7.35% |
| 2010 Q2 | -11.76 Million USD | -3.38% |
| 2009 Q4 | -12.28 Million USD | 9.51% |
| 2009 Q2 | -16.73 Million USD | -15.95% |
| 2009 Q3 | -13.57 Million USD | 18.89% |
| 2009 FY | - USD | -15.44% |
| 2009 Q1 | -14.43 Million USD | 13.78% |
| 2008 Q4 | -16.73 Million USD | -53.27% |
| 2008 Q2 | -11.12 Million USD | -4.91% |
| 2008 Q1 | -10.6 Million USD | -9.18% |
| 2008 FY | - USD | -79.11% |
| 2008 Q3 | -10.91 Million USD | 1.86% |
| 2007 Q4 | -9.71 Million USD | -19.09% |
| 2007 Q3 | -8.15 Million USD | -42.86% |
| 2007 Q2 | -5.7 Million USD | -6.92% |
| 2007 Q1 | -5.34 Million USD | -16.15% |
| 2007 FY | - USD | -79.76% |
| 2006 Q2 | -3.54 Million USD | 6.9% |
| 2006 Q1 | -3.8 Million USD | -5.83% |
| 2006 FY | - USD | -12.45% |
| 2006 Q4 | -4.59 Million USD | -16.75% |
| 2006 Q3 | -3.93 Million USD | -11.23% |
| 2005 Q3 | -3.78 Million USD | -27.86% |
| 2005 Q4 | -3.59 Million USD | 5.12% |
| 2005 Q1 | -3.29 Million USD | -30.0% |
| 2005 Q2 | -2.96 Million USD | 10.21% |
| 2005 FY | - USD | -52.23% |
| 2004 Q2 | -2.07 Million USD | -86.95% |
| 2004 Q3 | -3.24 Million USD | -56.28% |
| 2004 Q1 | -1.1 Million USD | -1927.09% |
| 2004 FY | - USD | -11229.95% |
| 2004 Q4 | -2.53 Million USD | 21.7% |
| 2003 Q4 | -54.71 Thousand USD | -478.29% |
| 2003 Q3 | -9462.00 USD | -95.13% |
| 2003 FY | - USD | -452.66% |
| 2003 Q1 | -9074.00 USD | -315.07% |
| 2003 Q2 | -355.24 Thousand USD | 46.56% |
| 2002 FY | - USD | 64.01% |
| 2002 Q4 | 4219.00 USD | 133.46% |
| 2002 Q1 | 12.35 Thousand USD | 0.0% |
| 2002 Q2 | -18.27 Thousand USD | -247.92% |
| 2002 Q3 | -12.61 Thousand USD | 30.99% |
| 2001 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Editas Medicine, Inc. | -163.11 Million USD | 377.069% |
| Dynavax Technologies Corporation | 9.66 Million USD | -4575.636% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | -359.941% |
| Perrigo Company plc | 646.2 Million USD | 30.061% |
| Illumina, Inc. | -608 Million USD | 174.333% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 95.815% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 200.653% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 104.007% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 86.12% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 535.435% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 90.289% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 1312.207% |
| Waters Corporation | 1.02 Billion USD | 55.789% |
| Biogen Inc. | 2.37 Billion USD | 80.987% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 616.942% |
| Evolus, Inc. | -41.81 Million USD | 1180.954% |
| Adicet Bio, Inc. | -136.53 Million USD | 431.012% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 484.145% |
| bluebird bio, Inc. | -167.16 Million USD | 370.366% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 401.081% |
| FibroGen, Inc. | -261.4 Million USD | 272.891% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 73.05% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 1117.058% |
| Homology Medicines, Inc. | -47.75 Million USD | 1046.367% |
| Geron Corporation | -174.78 Million USD | 358.578% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 298.117% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 590.825% |
| Myriad Genetics, Inc. | -67.8 Million USD | 766.588% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 548.24% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 189.262% |
| Zoetis Inc. | 3.68 Billion USD | 87.735% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 993.67% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 61.175% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | -45.656% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 90.186% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 1352.555% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 296.49% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 269.907% |
| Verastem, Inc. | -83.16 Million USD | 643.428% |
| Nektar Therapeutics | -243.1 Million USD | 285.905% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 300.873% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | 613.664% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 202.903% |
| OPKO Health, Inc. | -65.51 Million USD | 789.827% |
| Exelixis, Inc. | 196.6 Million USD | -129.879% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | -8.615% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | -317.218% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 910.58% |
| uniQure N.V. | -253.1 Million USD | 278.565% |
| Imunon, Inc. | -20.78 Million USD | 2274.675% |
| Blueprint Medicines Corporation | -474.61 Million USD | 195.225% |
| Insmed Incorporated | -654.73 Million USD | 169.027% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 230.823% |
| TG Therapeutics, Inc. | 26.1 Million USD | -1631.598% |
| Incyte Corporation | 919.42 Million USD | 50.845% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 189.441% |